Diabetes: Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The Annals of Pharmacotherapy

• Publication date

  2007-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1345/aph.1H459PMID 17190843
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

  2006cited by this paper
• Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

  2006cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• MK-431 (Merck).

  2005cited by this paper
• Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

  2004cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• On the Physiology of GIP and GLP-1

  2004cited by this paper
• Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.

  2004cited by this paper
• Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes

  2004cited by this paper
• The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.

  2004cited by this paper
• Beta- and Alpha-Cell Dysfunction in Type 2 Diabetes

  2004cited by this paper
• GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.

  2004cited by this paper
• Incretins, insulin secretion and Type 2 diabetes mellitus

  2004cited by this paper
• The Role of GLP-1 in the Life and Death of Pancreatic Beta Cells

  2004cited by this paper
• Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway.

  2003cited by this paper
• The glucagon-like peptides: a double-edged therapeutic sword?

  2003cited by this paper
• 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

  2003cited by this paper
• Enhancing incretin action for the treatment of type 2 diabetes.

  2003cited by this paper
• Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

  2003cited by this paper
• Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.

  2003cited by this paper
• Gastric inhibitory polypeptide: the neglected incretin revisited.

  2002cited by this paper
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.

  2002cited by this paper
• Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

  2002cited by this paper
• Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.

  2002cited by this paper
• Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.

  2002cited by this paper
• NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.

  2002cited by this paper
• Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo.

  2002cited by this paper
• Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.

  2002cited by this paper
• Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.

  2002cited by this paper
• Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells.

  2002cited by this paper
• The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.

  2002cited by this paper
• Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes.

  2001cited by this paper
• Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.

  2001cited by this paper
• A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

  2001cited by this paper
• The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.

  2001cited by this paper
• Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1

  2001cited by this paper
• Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

  2000cited by this paper
• Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

  2000cited by this paper
• Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

  2000cited by this paper
• Printed in U.S.A. Copyright © 2000 by The Endocrine Society Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist*

  2000cited by this paper
• NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV.

  1999cited by this paper
• The glucagon-like peptides.

  1999cited by this paper
• Effect of GIP and GLP-1 antagonists on insulin release in the rat.

  1999cited by this paper
• GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.

  1999cited by this paper
• Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice.

  1999cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

  1999cited by this paper
• Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

  1999cited by this paper
• Normalization of fasting glycaemia by intravenous GLP‐1 ([7‐36 amide] or [7‐37]) in Type 2 diabetic patients

  1998cited by this paper
• Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

  1998cited by this paper
• Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide

  1998cited by this paper
• Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDM

  1996cited by this paper
• Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide

  1995cited by this paper
• Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

  1995cited by this paper
• Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

  1995cited by this paper
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  1993cited by this paper
• Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

  1993cited by this paper
• Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man

  1993cited by this paper
• Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

  1993cited by this paper
• Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable

  1993cited by this paper
• Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

  1992cited by this paper
• Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects

  1992cited by this paper
• Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue.

  1991cited by this paper
• Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.

  1989cited by this paper
• Suppression by insulin treatment of glucose-induced inhibition of insulin release in non-insulin-dependent diabetics.

  1989cited by this paper
• Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

  1988cited by this paper
• Glucagon-like peptide-1 7-36: a physiological incretin in man.

  1987cited by this paper
• Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

  1987cited by this paper
• Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

  1987cited by this paper
• Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

  1986cited by this paper
• The incretin concept today

  1979cited by this paper
• Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus.

  1978cited by this paper
• NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE.

  1964cited by this paper
• PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.

  1964cited by this paper
• NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE

  1964cited by this paper
• 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels

  year unknowncited by this paper

• Review of pharmaceutical and therapeutic approaches for type 2 diabetes and related disorders.

  2022cites this paper
• The Involvement of the Mammalian Target of Rapamycin, Protein Tyrosine Phosphatase 1b and Dipeptidase 4 Signaling Pathways in Cancer and Diabetes: A Narrative Review.

  2020cites this paper
• Current situation analysis of diabetic home care patients

  2019cites this paper
• Insights into replicative senescence of human testicular peritubular cells

  2019cites this paper
• Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios

  2018cites this paper
• Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

  2017cites this paper
• Fc-fusion Proteins in Therapy: An Updated View.

  2017cites this paper
• Individualisation du traitement de l’hyperglycémie du diabète de type 2 : choix selon la classe thérapeutique, ou selon la molécule

  2017cites this paper
• The Effect of Sitagliptin on Lipid Metabolism of Fatty Liver Mice and Related Mechanisms

  2017cites this paper
• Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis

  2016cites this paper
• Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records.

  2016cites this paper
• Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors.

  2016cites this paper
• Treating the elderly diabetic patient: special considerations

  2014cites this paper
• The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose?

  2014cites this paper
• Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

  2014cites this paper
• Traitement du diabète par administration d'inhibiteurs de dipeptidyl peptidase-iv

  2013cites this paper
• Ação do inibidor da enzima dipeptidil peptidase 4 sobre o pré-condicionamento isquêmico em pacientes portadores de diabetes mellitus tipo 2 e doença arterial coronariana estável

  2012cites this paper
• Saxagliptin

  2012cites this paper
• The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.

  2011cites this paper
• Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes

  2011cites this paper
• Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

  2011cites this paper
• Aminotétrahydropanes utilisés comme inhibiteurs de la dipeptyl peptidase-iv pour traiter ou prévenir le diabète

  2010cites this paper
• Xenin-25 Potentiates Glucose-dependent Insulinotropic Polypeptide Action via a Novel Cholinergic Relay Mechanism*

  2010cites this paper
• Linagliptin (BI 1356), a potent and selective DPP‐4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

  2010cites this paper
• Prospective controlled study of effect of laparoscopic sleeve gastrectomy on small bowel transit time and gastric emptying half-time in morbidly obese patients with type 2 diabetes mellitus.

  2010cites this paper
• Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.

  2010cites this paper
• The incretin system and cardiometabolic disease.

  2010cites this paper
• This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Management of Global Cardiovascular Risk in Older Subjects with Diabetes Mellitus

  2010cites this paper
• This Month's Featured Articles

  2010cites this paper
• Sitagliptin

  2010cites this paper
• Medical information about diabetes—how to keep up to date

  2010cites this paper
• Combinaison thérapeutique contenant des aminotetrahydropyrannes en tant qu'inhibiteurs de dipeptidyl peptidase-IV pour le traitement ou la prévention des diabètes

  2009cites this paper
• Use of serum c-peptide level to simplify diabetes treatment regimens in older adults.

  2009cites this paper
• Pharmacologic management of the older patient with type 2 diabetes mellitus.

  2009cites this paper
• Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

  2009cites this paper
• Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.

  2009cites this paper
• Bibliography. Current world literature. Diabetes and the endocrine pancreas.

  2008cites this paper
• Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study

  2008cites this paper
• Enzymatic C-Demethylation of 1-[2-(5-tert-Butyl-[1,3,4] oxadiazole-2-carbonyl)-4-fluoro-pyrrolidin-1-yl]-2-(2-hydroxy-1,1-dimethyl-ethylamino)-ethanone (LC15-0133) in Rat Liver Microsomes

  2008cites this paper
• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  2008cites this paper
• Third‐Line Agent Selection for Patients with Type 2 Diabetes Mellitus Uncontrolled with Sulfonylureas and Metformin

  2008cites this paper
• Necesidades de mejora y limitaciones en el tratamiento de la diabetes mellitus. Perspectiva del endocrinólogo

  2007cites this paper
• The year's new drugs and biologics--2006.

  2007cites this paper